Real-world data indicates that second-line therapies have limited efficacy in patients with advanced urothelial cancer (aUC) who were initially treated with enfortumab vedotin and pembrolizumab. The data suggests that these second-line therapies may not be highly effective for this specific patient population. The findings are based on real-world data, which provides insight into the treatment outcomes of patients with aUC.